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Murein Lytic Enzyme TgaA of Bifidobacterium bifidum MIMBb75
Modulates Dendritic Cell Maturation through Its Cysteine- and
Histidine-Dependent Amidohydrolase/Peptidase (CHAP) Amidase
Domain
Simone Guglielmetti,a Ivan Zanoni,b Silvia Balzaretti,a Matteo Miriani,a Valentina Taverniti,a Ivano De Noni,a Ilaria Presti,a
Milda Stuknyte,a Alessio Scarafoni,a Stefania Arioli,a Stefania Iametti,a Francesco Bonomi,a Diego Mora,a Matti Karp,c
Francesca Granuccib
Department of Food Environmental and Nutritional Sciences, Università degli Studi di Milano, Milan, Italya; Department of Biotechnology and Biosciences, University of
Milano-Bicocca, Milan, Italyb; Department of Chemistry and Bioengineering, Tampere University of Technology, Tampere, Finlandc
Bifidobacteria are Gram-positive inhabitants of the human gastrointestinal tract that have evolved close interaction with their
host and especially with the host’s immune system. The molecular mechanisms underlying such interactions, however, are
largely unidentified. In this study, we investigated the immunomodulatory potential of Bifidobacterium bifidum MIMBb75, a
bacterium of human intestinal origin commercially used as a probiotic. Particularly, we focused our attention on TgaA, a protein
expressed on the outer surface of MIMBb75’s cells and homologous to other known bacterial immunoactive proteins. TgaA is a
peptidoglycan lytic enzyme containing two active domains: lytic murein transglycosylase (LT) and cysteine- and histidine-de-
pendent amidohydrolase/peptidase (CHAP). We ran immunological experiments stimulating dendritic cells (DCs) with the B.
bifidum MIMBb75 and TgaA, with the result that both the bacterium and the protein activated DCs and triggered interleukin-2
(IL-2) production. In addition, we observed that the heterologous expression of TgaA in Bifidobacterium longum transferred to
the bacterium the ability to induce IL-2. Subsequently, immunological experiments performed using two purified recombinant
proteins corresponding to the single domains LT and CHAP demonstrated that the CHAP domain is the immune-reactive region
of TgaA. Finally, we also showed that TgaA-dependent activation of DCs requires the protein CD14, marginally involves TRIF,
and is independent of Toll-like receptor 4 (TLR4) andMyD88. In conclusion, our study suggests that the bacterial CHAP domain
is a novel microbe-associated molecular pattern actively participating in the cross talk mechanisms between bifidobacteria and
the host’s immune system.
The human intestinal microbiota comprises more than 1,000microbial taxa, which through evolution have adopted differ-
ent strategies to interact with the host, from commensalism or
symbiosis to parasitism (1). A well-established and rapidly grow-
ing body of literature demonstrates how deeply the intestinal mi-
crobiota is involved in several host physiologic dysfunctions such
as obesity, diabetes, autoimmune diseases, and cancer (1, 2). Fur-
thermore, there is scientific evidence that certain members of the
microbiota more than others play a crucial role in maintaining a
physiological homeostasis in the host (3, 4). For instance, bifido-
bacteria are Gram-positive inhabitants of the human gastrointes-
tinal tract that have evolved a deep interaction with the host (5, 6,
7, 8). In particular, bifidobacteria, which colonize the human in-
testine immediately after birth, are the predominant taxon of the
microbiota of breast-fed infants and affect the maturation of
the host’s immune system during the neonatal period, especially
the TH1/TH2 balance (9, 10). Accordingly, a relation has been
established between allergic diseases and bifidobacterial coloniza-
tion (11, 12, 13, 14). In fact, allergic patients have exhibited lower
Bifidobacterium counts than healthy control subjects. In addition,
the species Bifidobacterium adolescentis and Bifidobacterium
longum subsp. longum have been isolated from allergic infants as
the predominant bifidobacteria, whereas the predominant ones
isolated from age-matched healthy infants have been Bifidobacte-
rium breve, Bifidobacterium longum subsp. infantis, and Bifidobac-
terium bifidum (13). These findings testify to a plausible link be-
tween bifidobacteria and atopy/tolerance balance (15, 16), with
certain species such as B. bifidum being potentially crucial in lim-
iting the development of a long-termTH2-skewed immunological
memory in infants and, therefore, in preventing allergies. The
ability of B. bifidum strains to interact with the host immune sys-
tem has been reported in several studies (17, 18), but very little
information is available concerning the molecular components
that support the host-B. bifidum cross talk (8, 19).
Whereas adaptive immunity recognizes amicroorganismby its
specific microbial molecular components known as antigens, in-
nate immunity relies on recognizing microbe-associated molecu-
lar patters (MAMPs), that is, conserved structures present within
a class of microorganisms but not in the host tissue (20). Several
MAMPs have been identified, such as lipopolysaccharide (LPS,
also referred to as endotoxin), peptidoglycan, lipoteichoic acid,
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and bacterial CpGDNAmotifs. However,many other yet unchar-
acterized MAMPs govern the intricate mechanisms of host-mi-
crobiota interactions and either help maintain or compromise
immunological homeostasis. Consequently, it is critically impor-
tant to study the immunological role of microbial molecular cell
components to decipher the operating principles of the immune
system. In this regard, our use of a reductionist molecular ap-
proach allowed us to define the immunological role of an intra-
molecular region belonging to an outer surface enzyme, TgaA,
identified in an accompanying paper (21) by comparative
genomic analysis in strain B. bifidum MIMBb75.
MATERIALS AND METHODS
Bifidobacterial culture conditions. Bifidobacteria were grown under an-
aerobic conditions (Anaerocult A System; Merck, Darmstadt, Germany)
at 37°C in prereduced DeMan-Rogosa-Sharpe (MRS) broth (Difco Lab-
oratories, Inc., Detroit, MI) supplemented with 0.05% L-cysteine hydro-
chloride (cMRS).
Overproduction and purification of TgaA-derived recombinant
proteins. All enzymes and reagents for molecular biology reactions were
from Fermentas (Vilnius, Lithuania) or New England BioLabs (Euro-
Clone S.p.A., Pero, Italy). Commercial kits for the extraction and purifi-
cation of nucleic acids were from MoBio Laboratories (Cabru s.a.s., Ar-
core, Italy) or Qiagen s.r.l. (Milan, Italy). Vectors pET-Tga, pET-CHAP
(where CHAP is cysteine- and histidine-dependent amidohydrolase/pep-
tidase) and pET-LT (where LT is lytic murein transglycosylase) (pre-
pared as described in the accompanying paper [21]) were used for the
isopropyl--D-thiogalactopyranoside (IPTG)-dependent overexpression
inEscherichia coli of the recombinant proteinsSP-TgaA-His (containing
both domains of TgaA protein; also named here recombinant TgaA, or
rTgaA, and SPPelB-TgaA in the accompanying paper [21]), protein SP-
TgaA-CHAP-His (containing only the LT domain; rLT), and SP-
TgaA-LT-His (containing only the CHAP domain; rCHAP), respec-
tively. In brief, mutant E. coli strains were grown in 2 YT (yeast extract,
tryptone) broth at 37°C for 2 h before 1 mM IPTG was added, and incu-
bation was prolonged for 4 h. Afterwards, proteins were extracted under
denaturing conditionswith PerfectProNi-nitrilotriacetic acid (NTA) aga-
rose (5 Prime; Eppendorf Italia, s.r.l., Milan, Italy) according to the man-
ufacturer’s instructions. The molecular mass of recombinant SP-TgaA-
His, SP-TgaA-CHAP-His, and SP-TgaA-LT-His proteins was
confirmed by reverse-phase high-pressure liquid chromatography (RP-
HPLC)/electrospray ionization mass spectrometry (ESI-MS) analysis un-
der conditions reported by Taverniti et al. (22). A further purification and
removal of residue LPS from recombinant proteins was carried out by
analytical or preparative RP-HPLC. After acidification to pH 2 by addi-
tion of 0.1% of trifluoroacetic acid (TFA), aliquots of 0.1 ml of Ni-NTA-
purified protein were injected into aWaters 600 HPLC system fitted with
aVYDACC4 (4.6 by 250mm; 300-Å pore size; 5-mparticle size) column
(Grace, Deerfield, IL). The eluents used for the separation were solvent A,
consisting of 0.1% trifluoroacetic acid (TFA) inMilliQ-treated water, and
solvent B, consisting of 0.1% TFA in acetonitrile. The protein separation
was performed at room temperature by using a linear elution gradient
(60% to 30% of solvent A in 25min). Proteins were eluted at a flow rate of
0.8 ml min1 and monitored at 220 and 280 nm. Protein-containing
fractions were collected, and the degree of purification was checked by
SDS-PAGE. Finally, eluted fractions were lyophilized and stored at
20°C.
Generation of SP-TgaA-LT-His-specific antibodies and immu-
nogold labeling.The preparation of an antibody against the recombinant
protein SP-TgaA-LT-His (rCHAP) was raised in rabbits by Primm
s.r.l. (Milan, Italy). Immunogold labeling was performed as described in
the companion paper (21).
Expression of TgaA in Bifidobacterium longum NCC2705. All clon-
ing steps for the preparation of the vectors used to transform B. longum
NCC2705 were carried out in E. coli XL1-Blue (see Fig. S1 in the supple-
mentalmaterial). In detail, the promoter region fromphage T5 (PT5) was
obtained from vector pGBL8b (23) through digestion with restriction
enzymes BamHI and HindIII. The resulting DNA fragment was intro-
duced in vector pUC19 in the same restriction sites, yielding vector pUC-
T5. At the same time, the DNA region containing the gene coding for the
chloramphenicol acetyltransferase of pC194 (a natural plasmid of Staph-
ylococcus aureus) with its original promoter was obtained through PCR
with primers catBC-f (5=-CATGGATCCATCGATCTGCA-3=; restriction
sites BamHI and ClaI are underlined) and catS-r 5=-TACCCGGAGCTC
CTCTAGA-3=; the restriction site SalI is underlined) from vector
pGBL8b. The resulting amplicon was digested with BamHI and SalI and
cloned in pUC-T5 digested with the same restriction enzymes, yielding
vector pUT5cat. Subsequently, the gene tgaA was amplified from the
chromosomal DNA of B. bifidum MIMBb75 with primers tgaDie-f (5=-A
ACTTCGTGAGATCTGCCGCGTCCCGCGCCAT-3=; restriction site
BglII is underlined) and tgaC-r (5=-GCTCATCGATTTTACTTTCCTT-
3=; restriction site ClaI is underlined); the amplicon was digested with
enzymes BglII and ClaI and cloned in sites BamHI and ClaI of vector
pUT5cat, yielding vector pUTgaCat. Plasmid pUTgaCat was then di-
gested with HindIII and XbaI; then, the restriction fragment containing
the gene tgaA was extracted from the agarose gel, purified, and cloned in
the same restriction sites of vector pGOSBif33 (24), yielding the final
vector pTgaBif5, which was employed for the expression of tgaA in B.
longum. The control vector pT5CatBif21 (empty vector) was prepared
according to the same protocol, with the exception of the cloning step for
the introduction of gene tgaA, which was not carried out. Finally, vectors
pTgaBif5 and pT5CatBif21 were introduced in B. longum NCC2705
(courteously provided byNestlé Research Center, Lausanne, Switzerland)
as previously described (23, 24).
RT-PCR. The expression of the gene tgaA from plasmid pTgaBif5 was
verified in B. longum NCC2705 by reverse transcription-PCR (RT-PCR).
For the extraction of RNA, 20 ml of exponentially growing cultures of B.
bifidum MIMBb75 were centrifuged for 10 min at 4,000 g at 4°C in the
presence of RNA-Later (Ambion). The pellet was then immediately frozen
in liquid nitrogen and subjected to RNA extraction using a previously
described method, which includes a DNase treatment (25). The quality
and integrity of the RNA were checked by Experion (Bio-Rad) analysis.
cDNA was synthesized using an iScript cDNA synthesis kit (Bio-Rad),
according to the supplier’s instructions. PCRwas performedwith primers
B-7x (5=-CACAGTTCATACCGTCCACA-3=) and Bext-f-II (5=-GTAGT
TGGTGGTCTCCGTGA-3=) according to the following PCR protocol: 1
cycle of 95°C for 3 min, 39 cycles consisting of 95°C for 30 s, 58°C for 40 s
and 72°C for 30 s, and a final elongation step of 72°C for 7 min. The
obtainment of an ampliconwith the expected size of 260 bp demonstrated
the presence of tgaA mRNA in the recombinant NCC2705 strain.
Preparation and analysis of immunofluorescent B. bifidum
MIMBb75. B. bifidum MIMBb75 cells were cultivated until early station-
ary growth phase, harvested by centrifugation, washed once with deion-
ized sterile water, and incubated at room temperature for 10 min with
SP-TgaA-LT-His antiserum (1:100 diluted in deionized water). Sub-
sequently, bacterial cells were centrifuged, resuspended in a solution of
Cy5-conjugated goat anti-rabbit secondary antibody (Molecular Probes,
Eugene, OR) (1:10 diluted in deionized water), and incubated for 10 min
at room temperature in the dark. Afterwards, stained cells were visualized
with a fluorescence optical digital microscope (Leica DM1000; Leica Mi-
crosystems, Wetzlar, Germany) at a magnification of1,000.
Study of BMDC activation. Dendritic cells (DCs) were obtained in
vitro frombonemarrow hematopoietic precursors isolated fromC57BL/6
mouse femurs as described previously (26). In brief, hematopoietic pre-
cursors were recovered from mouse femoral bone marrow and resus-
pended in conditioned medium (complete medium supplemented with
10% of the growth supernatant of granulocyte-macrophage colony-stim-
ulating factor [GM-CSF]-transduced B16 cells). About 7 106 cells were
plated in 100-mm suspension plates. The proportion of CD11c cells
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(corresponding to dendritic cells) was monitored periodically by flow
cytometry until it reached 90% (ca. 8 days). The bone marrow-derived
dendritic cells (BMDCs)were then used for bacterial activation assays. On
the day of bacterial infection, BMDCswere plated at a concentration of 0.5
million per ml in 96-well plates (105 cells/well). After 1 h, BMDCs were
incubated with four different concentrations of bacterial cells for 2 h,
washed with saline, resuspended in a culture medium containing penicil-
lin G, streptomycin, tetracycline, and gentamicin, and incubated over-
night. Finally, interleukin-2 (IL-2) and tumor necrosis factor alpha
(TNF-) in the supernatant were quantified by enzyme-linked immu-
nosorbent assay (ELISA) using DuoSet kits (R&D Systems, Minneapolis,
MN). The same procedure was followed to prepare BMDCs from four
mutant mouse lines. Wild-type animals were supplied by Harlan Italy.
Ticam1Lps2 (Trif/) mice were purchased from The Jackson Labora-
tory. Myd88/ and Tlr4/ mice were provided by S. Akira (IFReC,
Japan). Cd14/mice were from CNRS d’Orléans (Orléans, France). D1
cell line was cultured in Iscove’s modified Dulbecco’s medium (IMDM;
Sigma, St. Louis, MO) containing 10% heat-inactivated fetal bovine se-
rum (Gibco-BRL, Gaithersburg, MD), 100 IU of penicillin, 100 g ml1
of streptomycin, 2 mM L-glutamine (all from Sigma), and 50 M -mer-
captoethanol (in complete IMDM) with 30% supernatant from R1 me-
dium (supernatant fromNIH 3T3 fibroblasts transfected with GM-CSF).
Unpaired Student’s t tests were run to determine statistically significant
differences.
RESULTS AND DISCUSSION
Recently, we generated a draft genome sequence of Bifidobacte-
rium bifidum MIMBb75, a probiotic strain with demonstrated
ability to interact with the host (19, 27–29). Comparative genom-
ics revealed in MIMBb75’s genome the presence of a gene encod-
ing TgaA, a peptidoglycan-lytic enzyme which contains two con-
served domains: lytic murein transglycosylase (LT; cd00254.3)
and cysteine- and histidine-dependent amidohydrolase/peptidase
(CHAP; pfam05257.4) (21).
The biomolecular composition of a bacterium’s cell wall
mainly determines the cross talk processes with the host. In fact,
most known bacterial molecules governing bacterial adhesion to
epithelia or interaction with immune cells are cell wall constitu-
ents (lipopolysaccharides, teichoic and lipoteichoic acids,murein,
and proteinaceous adhesins) or cell wall appendages (flagella, pili,
and fimbriae) (6, 8, 19, 22). Interestingly, TgaA protein was found
to be abundantly expressed and located on the outer surface of
FIG 1 ELISA quantification of cytokines produced by dendritic cells after stimulation with 12 different strains belonging to the genus Bifidobacterium and 10
g/ml of lipopolysaccharides (LPS) from E. coli. NT, sample not treated. One representative experiment out of three performed is shown. Black bars, bone
marrow-derived dendritic cells (BMDCs); white bars, D1 cell line. All strains were tested at four different multiplicities of induction (MOI; DC/bacteria ratio).
Strains belong to the following bifidobacterial species: B. bifidum (MIMBb75, DMS 20456T, NCC390); B. longum subsp. infantis (BNF01, BNF02); B. breve
(BBR02); B. pseudocatenulatum (DSM20438T, MIMBp287); B. longum subsp. longum (MIMBl8, MIMBl16, NCC2705); B. animalis subsp. lactis (BB12).
Guglielmetti et al.
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MIMBb75 bacterial cells (21). Furthermore, notably, a search of
the Conserved Domain Database (30) for the TgaA protein pro-
duced a significantmatch (E value of 8.30e-23) between theCHAP
module and the conserved domain COG3942, which has been
annotated as a surface antigen. The description of COG3942 orig-
inated from two studies that identified the CHAP domain-con-
taining protein as an immune-reactive molecule of Listeria mono-
cytogenes (31) and Streptococcus pyogenes (32). Stimulated by the
above data, we evaluated the potential contribution of the TgaA
protein to the immunomodulatory activity of the strain
MIMBb75.
We assessed the immunological properties of B. bifidum
MIMBb75 in parallel and independently of the TgaA protein
study and discovered through our immunological model a pecu-
liar immunomodulatory capacity of this strain. In particular, we
focused on dendritic cells (DCs), the sentinels of the immune
system present at various mucosal sites and especially in the intes-
tinal mucosa. At this site, they may sense the intestinal lumen
content (including bacteria) via transepithelial processes by re-
sponding to the ligation of the DCs’ specific microbe recognition
receptors (MRRs) to MAMPs (such as LPS, peptidoglycan, and
bacterial and viral nucleic acids) to trigger immune responses (33,
34). Particularly, upon activation and migration to secondary
lymphoid organs, DCs induce immunocompetence in lympho-
cytes through antigen presentation and cytokine production.
Hence, DCs form a link between innate and adaptive immunity
and are considered arbiters of immunological tolerance (34).
In DCs, a major outcome of the ligation of pattern recognition
receptors (PRRs) may be the production of interleukin-2 (IL-2),
which has several effects. In fact, DC-derived IL-2 increases
gamma interferon (IFN-	) production by the natural killer (NK)
cells (35), enhances T cell responses in bothmice (26) and humans
(36), regulates thymic development (37), and promotes regula-
tory T cell (Treg) expansion and function (38). Furthermore, it
has been linked with TH1-skewing stimuli (35). Inducing IL-2
production in DCs can thus steer the adaptive immune system
toward preventing TH2 cell-dominated immune responses, such
as those associated with allergy (39, 40).
Our experiments showed that out of 12 bifidobacterial strains
belonging to six different species and subspecies, the strain B. bi-
fidum MIMBb75 was among the strongest inducers of IL-2 pro-
duction by murine bone marrow-derived DCs (BMDCs) (Fig. 1).
Subsequently, we studied the potential immunomodulatory
activity of TgaA with the same immunological model we used for
bifidobacterial cells. Initially, we cloned a complete tgaA gene (in-
cluding the original signal sequence for exporting the protein at a
cell wall level) inBifidobacterium longumNCC2705 using a shuttle
vector previously developed and used for successful expression of
heterologous genes in B. longum (23, 24). We followed this strat-
egy because all of our previous efforts to knock out tgaA had been
unsuccessful since this species has been proved to be recalcitrant
to geneticmanipulation (41, 42).We selectedB. longumNCC2705
as the host for tgaA expression after analysis of its whole genome
revealed that the tgaA gene as absent in this human intestinal
bacterium. Furthermore, our immunological data (Fig. 1) showed
that the strain NCC2705, unlikeMIMBb75, is incapable of induc-
ing IL-2 expression by BMDCs.Wenamed the recombinant strain
we obtained NCC:tga. After verifying by reverse transcription-
PCR (RT-PCR) and immunogold labeling (see Fig. S2A and B in
the supplemental material) that NCC:tga expressed the recom-
binant tgaA gene, we incubated BMDCs with supernatant-free
wild-type live cells and recombinant NCC2705 strains and then
measured by ELISA the levels of the secreted tumor necrosis factor
alpha (TNF-) and IL-2. Secretion by BMDCs of the TNF- cy-
tokine, the principal marker of DC activation, was induced by all
bacterial preparations (Fig. 2). In contrast, our experiments
showed a significant secretion of IL-2 only when DCs were stim-
ulated with the recombinant strain NCC:tga (i.e., NCC2705
transformed with the vector containing the gene tgaA) and not
with control preparations (wild-type NCC2705 and NCC2705
FIG 2 ELISA quantification of cytokine production by BMDCs after stimulation with E. coli lipopolysaccharides (LPS), Bifidobacterium longumNCC2705, and
its recombinant strainsNCC:tga (expressingTgaAprotein) andNCC:tga (harboring the empty vector). All sampleswere tested at four differentmultiplicities
of infection (MOI; BMDC/bacteria ratio). One representative experiment out of two performed is shown.
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transformed with the empty vector) (Fig. 2). Therefore, our data
suggest that the TgaAproteinmay be directly involved in inducing
the cytokine IL-2 in dendritic cells.
To further test our hypothesis, we thoroughly purified from E.
coli cells the recombinant proteins rTgaA, rLT, and rCHAP by
Ni-NTA affinity chromatography and subsequent RP-HPLC to
remove any residual LPS and extraneous proteins (Fig. 3). Purified
proteins were then used to stimulate two dendritic cell models:
BMDCs and the D1 cell line, which is a long-term growth factor-
dependent immature myeloid (CD11c CD8) DC line of
splenic origin. Our results show clearly that the rTgaA protein can
in vitro activate dendritic cells and induce dose-dependent secre-
tion of IL-2 (Fig. 4). A similar stimulatory effect was found with
the recombinant protein rCHAP,whereas rLT activated both den-
dritic cell models only marginally but could not markedly trigger
IL-2 expression (Fig. 4). Therefore, the TgaA protein activates
DCs and triggers IL-2 secretion by DCs by means of the CHAP
domain.
Finally, we studied the pathway induced by the protein TgaA in
DCs. Since TgaA can induce TNF- production by DCs and since
the cluster of differentiation 14 (CD14) protein is essential in in-
ducing such cytokines in LPS-stimulated DCs (43), we first tested
if CD14 might have a role also in recognizing TgaA. As shown in
Fig. 5, BMDC activation was totally abolished in the absence of
CD14. Since CD14 is the best characterized as a coreceptor for
Toll-like receptor 4 (TLR4), we then tested if BMDCs isolated
FIG 3 Preparation of TgaA-derived recombinant proteins. (A) Functionalmap of the recombinant proteins originated from a tgaA gene sequence and produced
by overexpression in E. coli BL21(DE3) pLysS using the pET26b() expression vector. (B) SDS-PAGE of the purified six-His-tagged TgaA-derived recombinant
proteins. Lane 1, SP-TgaA-His (containing both TgaA domains; rTgaA); lane 2, SP-TgaA-LT-His (containing the CHAP domain; rCHAP), lane 3,
SP-TgaA-CHAP-His (containing the LT domain; rLT). The relativemolecular masses (in kDa) of standard proteins are indicated on the left. aa, amino acids.
FIG 4 ELISA quantification of cytokine production by BMDCs and the D1 cell line stimulated with LPS or TgaA-derived recombinant proteins: rTgaA
corresponds to SP-TgaA-His, which contains both TgaA domains; rLT corresponds to SP-TgaA-CHAP-His, which contains only the LT domain; rCHAP
corresponds toSP-TgaA-LT-His, which contains only the CHAP domain. Statistically significant differences were determined by an unpaired Student’s t test
(*, P
 0.05; ***, P
 0.001). mBMDC, murine BMDCs.
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from knockout mice lacking the expression of TLR4 can be acti-
vated by TgaA. According to our data, the receptor TLR4 was not
necessary to induce TNF- in BMDCs by TgaA (Fig. 5). There-
fore, whereas LPS required TLR4 to induce TNF- (43), the pro-
tein TgaA directly activated the downstream pathways through
CD14 or involved CD14 for its presentation to a different un-
known receptor, independently of TLR4.
To test if other TLRs might be important to recognizing TgaA
by DCs, we used BMDCs derived from mice lacking the trans-
ducer of TLR signaling. In particular, TLR downstream signaling
can occur via two pathways, which depend on two proteins: (i) the
myeloid differentiation primary response gene 88 (MyD88) and
(ii) the Toll IL-1 receptor (TIR) domain-containing adaptor-in-
ducing IFN- (TRIF) (44). Surprisingly, we found that without a
functional TRIF or MyD88, production of TNF- by TgaA-stim-
ulated BMDCs was largely preserved (Fig. 5), suggesting that, in
dendritic cells, the downstream signaling induced by TgaA could
follow a CD14-dependent, TLR-independent signaling pathway.
Collectively, the above data show that TgaA is a cell wall pro-
tein of B. bifidum MIMBb75 and contains a C-terminal domain
that initiates a CD14-dependent andTLR4-independent signaling
pathway, which only partially involves the TRIF adapter protein.
A putative CHAP coding sequence is present inmany bacterial
genomes and is included in a number of different deduced protein
architectures (45). Interestingly, several proteins fromGram-pos-
itive bacteria that include the CHAP domain actively interact with
the host’s immune system. For instance, the Streptococcus pyogenes
SibA protein binds all immunoglobulin G (IgG) subclasses, the Fc
and Fab fragments, and also IgA and IgM (32). PcsB, another
CHAP-containing protein of Streptococcus spp. and a known an-
tigen of Streptococcus pneumoniae, is capable of activating T cells
in humans by inducing strong IL-17A responses (46). Further-
more, P40, a CHAP-containing protein produced by Lactobacillus
rhamnosus GG (perhaps the most studied probiotic strain so far),
can inhibit cytokine-induced epithelial cell apoptosis, reduce
TNF-induced colon epithelial damage, and promote cell growth
in human and mouse colon epithelial cells and cultured mouse
colon explants (47, 48). In addition, our study showed that TgaA
from B. bifidum MIMBb75 is a cell surface-exposed molecule ca-
pable alone through its C-terminal CHAPdomain of inducingDC
activation and IL-2 production. Based on observed induction of
IL-2 secretion, the TgaA stimulatory capacity here described may
stimulate dendritic cells to acquire TH1 stimulatory capacity (35).
Furthermore, the ability of B. bifidum MIMBb75 and its protein
TgaA to induce IL-2 by DCs, together with the previous observa-
tion that B. bifidum strains induce an immune response affecting
Treg/TH17 plasticity (49), supports the hypothesis that these com-
mensal bacteria have a key role inmucosal tolerance. The presence
of specific microbial stimuli, such as the CHAP-containing TgaA
protein, may then have served as a way for commensals to co-
evolve with the host and produce mechanisms for maintaining
homeostasis and controlled reactions in the adaptive immune sys-
tem (i.e., prevent an imbalance in T-helper cell subsets).
Interestingly, a BLASTP search revealed the presence of a gene
closely similar to theCHAPdomain of TgaA (withmore than 80%
identity in the amino acid sequence) not only in B. bifidum but
FIG 5 ELISA quantification of TNF- produced by rTgaA-stimulated
BMDCs isolated from wild-type (WT) and knockout mice. tlr4/, Toll-like
receptor 4 (TLR4) KO mutant mouse; cd14/, CD14 protein KO mutant
mouse; myd88/, myeloid differentiation primary response gene 88
(MYD88) KO mutant mouse; trif/, Toll IL-1 receptor (TIR) domain-con-
taining adaptor-inducing IFN- (TRIF) KO mutant mouse. Statistically sig-
nificant differences were determined by an unpaired Student’s t test (, P

0.001). nt, not treated.
FIG 6 DC-mediated host immune response to TgaA protein from Bifidobac-
terium bifidum MIMBb75: possible consequences of IL-2 production. The
contact between B. bifidum MIMBb75 and dendritic cells (DCs) determines
DC activation and IL-2 secretion. Reportedly, stimuli able to induce IL-2 pro-
duction by DCs are associated with a Th1-skewing of the immune responses,
Treg lymphocyte proliferation, and natural killer (NK) cell activation (for a
review, see reference 50).
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also in the genome of B. breve (e.g., GenBank accession number
WP_016462813), which is another Bifidobacterium species typ-
ically associated with healthy breast-fed infants (13). Therefore,
the presence in B. bifidum and other bifidobacteria of molecules
similar to the TgaA protein and capable of stimulating the im-
mune system could help explain the ability of these bacteria to
protect the host and nurture the immune system in early life (15,
16).
Conclusions. The results of this study can be summarized as
follows: (i) both the cells of B. bifidum MIMBb75 and its surface
protein TgaA can activate dendritic cells and trigger IL-2 produc-
tion; (ii) TgaA activates dendritic cells through its CHAP amidase
domain; and (iii) the TgaA-dependent activation of dendritic cells
requires the protein CD14, only marginally involves TRIF, and is
independent of TLR4 and MyD88.
The bacterium B. bifidum MIMBb75, which is of human ori-
gin, has probiotic properties (28), and its ability to interact with
the host may partly depend on the presence of the CHAP domain
of its TgaA surface protein. In conclusion, the bacterial CHAP
domain may well be considered a novel, potentially widespread
MAMP that may participate in the cross talk mechanisms among
Gram-positive bacteria and their mammalian host. The possible
physiological consequences of the ability of B. bifidum MIMBb75
and its TgaA protein to activate DCs are schematically summa-
rized in Fig. 6.
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